Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence and Rising Public Awareness
4.2.2 Technological Advancements and Improved Laboratory Automation
4.3 Market Restraints
4.3.1 Slow Turnaround Time of Results and Need of Multiple Diagnostic Test
4.3.2 High Cost
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Disease Type
5.1.1 Systemic Autoimmune Disease
5.1.1.1 Rheumatoid Arthritis
5.1.1.2 Psoriasis
5.1.1.3 Systemic Lupus Erythematosus (SLE)
5.1.1.4 Multiple Sclerosis
5.1.1.5 Other Systemic Autoimmune Diseases
5.1.2 Localized Autoimmune Disease
5.1.2.1 Inflammatory Bowel Disease
5.1.2.2 Type-1 Diabetes
5.1.2.3 Thyroid
5.1.2.4 Other Localized Autoimmune Diseases
5.2 By Diagnostic Technique
5.2.1 Immunofluorescence Assays (IFA)
5.2.2 Enzyme-linked Immunosorbant Assay (ELISA)
5.2.3 Western Blotting
5.2.4 Multiplex Immunoassay
5.2.5 Agglutination
5.2.6 Other Diagnostic Techniques
5.3 Geography
5.3.1 Europe
5.3.1.1 Germany
5.3.1.2 United Kingdom
5.3.1.3 France
5.3.1.4 Italy
5.3.1.5 Spain
5.3.1.6 Rest of Europe


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Biomerieux Inc.
6.1.3 Bio-rad Laboratories
6.1.4 Euroimmun AG
6.1.5 F. Hoffmann-la Roche
6.1.6 Inova Diagnostics Inc.
6.1.7 Myriad Genetics
6.1.8 Siemens Healthineers Inc.
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Trinity Biotech PLC


7 MARKET OPPORTUNITIES AND FUTURE TRENDS